Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25340011 | 1.00 | EPHX2 (0.47) | EPHX2AKR1C3TP53MAPTTRPV1 | |
| SCHEMBL25429357 | 0.77 | TP53 (0.42) | EPHX2AKR1C3TP53MAPTTRPV1 | |
| SCHEMBL30482521 | 0.74 | TP53 (0.45) | AKR1C3TP53MAPTACP1RAB9A | |
| SCHEMBL25377073 | 0.74 | TP53 (0.45) | AKR1C3TP53MAPTACP1RAB9A | |
| SCHEMBL25429117 | 0.72 | HSD17B10 (0.55) | EPHX2AKR1C3TP53MAPTTRPV1 | |
| SCHEMBL30519396 | 0.71 | KIF11 (0.62) | EPHX2AKR1C3TP53MAPTACP1 | |
| SCHEMBL25977664 | 0.71 | KIF11 (0.62) | EPHX2AKR1C3TP53MAPTACP1 | |
| SCHEMBL25339701 | 0.71 | TEAD1 (0.40) | EPHX2AKR1C3TP53MAPTACP1 | |
| SCHEMBL30544052 | 0.71 | TEAD1 (0.40) | EPHX2AKR1C3TP53MAPTACP1 | |
| SCHEMBL25977672 | 0.70 | TP53 (0.43) | EPHX2AKR1C3TP53MAPTACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146511-A1 | COMPOUNDS AND METHODS OF USE THEREOF | VIVACE THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |